Combining golimumab and guselkumab into JNJ-78934804, a fixed-dose co-antibody therapy, helped overcome treatment failure in inflammatory bowel disease and exceeded dose-dependent benefits of either ...

I'm 67 and in decent shape. I run 3-4 miles three times a week and lift weights three days a week. I take 20 mg of ...

For the first time, therapeutically effective medications are now available for Alzheimer's disease. Effective symptomatic ...